Detalles de la búsqueda
1.
Adding new experimental arms to randomised clinical trials: Impact on error rates.
Clin Trials
; 17(3): 273-284, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32063029
2.
Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer.
Acta Oncol
; 58(3): 326-333, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30657353
3.
Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab.
J Med Genet
; 54(8): 567-571, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28283541
4.
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
Lancet Oncol
; 15(6): 631-9, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24703531
5.
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Eur J Cancer
; 190: 112945, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37441940
6.
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Lancet
; 377(9783): 2103-14, 2011 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-21641636
7.
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Lancet Oncol
; 12(7): 642-53, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21641867
8.
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Lancet
; 370(9582): 143-152, 2007 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-17630037
9.
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
Eur J Cancer
; 102: 31-39, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30114658
10.
Randomized controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose deaths.
Addiction
; 112(3): 502-515, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27776382
11.
External data required timely response by the Trial Steering-Data Monitoring Committee for the NALoxone InVEstigation (N-ALIVE) pilot trial.
Contemp Clin Trials Commun
; 5: 100-106, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28424796
12.
Clarification re naloxone administered to study subject versus other overdose victim in the N-ALIVE pilot randomized trial.
Addiction
; 114(7): 1325, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31161681
13.
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
Cancer Treat Rev
; 38(6): 618-25, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22118887
14.
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
J Clin Oncol
; 27(35): 5931-7, 2009 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19884549
15.
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
J Clin Oncol
; 27(33): 5519-28, 2009 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19858398
16.
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
J Clin Oncol
; 26(16): 2690-8, 2008 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18509181
Resultados
1 -
16
de 16
1
Próxima >
>>